To produce concentrations of zidovudine (AZT) in plasma and cerebrospinal fluid that would provide constant inhibition of the replication of human immunodeficiency virus (HIV), we gave AZT by continuous intravenous infusion to 21 children ranging in age from 14 months to 12 years who had acquired HIV infection through transfusions or perinatally. All patients were symptomatic before AZT treatment (Class P2 of the Centers for Disease Control); 13 (62 percent) had evidence of neurodevelopmental abnormalities. The mean CD4/CD8 ratio was 0.18; 11 patients had CD4 counts below 0.2 x 10(9) per liter. We administered AZT at four dose levels: 0.5, 0.9, 1.4, and 1.8 mg per kilogram of body weight per hour. The plasma drug concentrations achieved at the respective dose levels were 1.9 +/- 0.3, 2.8 +/- 1.4, 3.1 +/- 1.1, and 4.5 +/- 1.0 microM. The steady-state cerebrospinal fluid:plasma ratio was 0.24 +/- 0.07. The only evidence of toxicity was bone marrow suppression. Transfusion was required in 14 patients because of low levels of hemoglobin (5 mmol per liter [less than 8 g per deciliter]). Dose-limiting neutropenia (less than 0.5 x 10(9) polymorphonuclear leukocytes per cubic millimeter) occurred in most patients who received doses of 1.4 mg per kilogram per hour or more. Improvement in neurodevelopmental abnormalities occurred in all 13 children who had presented with encephalopathy before treatment. Serial measurements of IQ before therapy and after three and six months of continuous therapy with AZT showed that IQ scores, including those for verbal and performance IQ, rose in these 13 patients and in 5 other children who had no detectable evidence of encephalopathy before treatment. Most patients also had increased appetite and weight, decreased lymphadenopathy and hepatosplenomegaly, decreased immunoglobulin levels, and increased numbers of CD4 cells. In some patients the improvement in the features of encephalopathy occurred despite the absence of immunologic improvement. We conclude that AZT is beneficial in children with symptomatic HIV infection, especially those with encephalopathy (which may be subclinical), and that the optimal continuous intravenous dose of AZT in children is between 0.9 and 1.4 mg per kilogram per hour.
Source Information
Pediatric Branch, National Cancer Institute, Bethesda, MD 20892.
This article has been cited by other articles:
Van Rie, A., Mupuala, A., Dow, A.
(2008). Impact of the HIV/AIDS Epidemic on the Neurodevelopment of Preschool-Aged Children in Kinshasa, Democratic Republic of the Congo. Pediatrics
122: e123-e128
[Abstract][Full Text]
Jeremy, R. J., Kim, S., Nozyce, M., Nachman, S., McIntosh, K., Pelton, S. I., Yogev, R., Wiznia, A., Johnson, G. M., Krogstad, P., Stanley, K., for the Pediatric AIDS Clinical Trials Group 338,
(2005). Neuropsychological Functioning and Viral Load in Stable Antiretroviral Therapy-Experienced HIV-Infected Children. Pediatrics
115: 380-387
[Abstract][Full Text]
Pessina, A., Albella, B., Bayo, M., Bueren, J., Brantom, P., Casati, S., Croera, C., Gagliardi, G., Foti, P., Parchment, R., Parent-Massin, D., Schoeters, G., Sibiril, Y., Van Den Heuvel, R., Gribaldo, L
(2003). Application of the CFU-GM Assay to Predict Acute Drug-Induced Neutropenia: An International Blind Trial to Validate a Prediction Model for the Maximum Tolerated Dose (MTD) of Myelosuppressive Xenobiotics. Toxicol Sci
75: 355-367
[Abstract][Full Text]
Gwilt, P. R., Manouilov, K. K., McNabb, J., Swindells, S. S.
(2003). Pharmacokinetics of Hydroxyurea in Plasma and Cerebrospinal Fluid of HIV-1-Infected Patients. J Clin Pharmacol
43: 1003-1007
[Abstract][Full Text]
Resino, S, Bellon, J M, Sanchez-Ramon, S, Gurbindo, D, Ruiz-Contreras, J, Leon, J A, Ramos, J T, Munoz-Fernandez, M A
(2002). Impact of antiretroviral protocols on dynamics of AIDS progression markers. Arch. Dis. Child.
86: 119-124
[Abstract][Full Text]
Hayes, K. A., Phipps, A. J., Francke, S., Mathes, L. E.
(2000). Antiviral Therapy Reduces Viral Burden but Does Not Prevent Thymic Involution in Young Cats Infected with Feline Immunodeficiency Virus. Antimicrob. Agents Chemother.
44: 2399-2405
[Abstract][Full Text]
Meng, Q., Su, T., Olivero, O. A., Poirier, M. C., Shi, X., Ding, X., Walker, V. E.
(2000). Relationships between DNA Incorporation, Mutant Frequency, and Loss of Heterozygosity at the TK Locus in Human Lymphoblastoid Cells Exposed to 3'-Azido-3'-deoxythymidine. Toxicol Sci
54: 322-329
[Abstract][Full Text]
Clifford, D. B.
(2000). Human Immunodeficiency Virus-Associated Dementia. Arch Neurol
57: 321-324
[Full Text]
Raskino, C., Pearson, D. A., Baker, C. J., Lifschitz, M. H., O'Donnell, K., Mintz, M., Nozyce, M., Brouwers, P., McKinney, R. E., Jimenez, E., Englund, J. A., for the Pediatric AIDS Clinical Trials Group 152 S,
(1999). Neurologic, Neurocognitive, and Brain Growth Outcomes in Human Immunodeficiency Virus-Infected Children Receiving Different Nucleoside Antiretroviral Regimens. Pediatrics
104
: e32-e32
[Abstract][Full Text]
Horn, T. F. W., Huitron-Resendiz, S., Weed, M. R., Henriksen, S. J., Fox, H. S.
(1998). Early physiological abnormalities after simian immunodeficiency virus infection. Proc. Natl. Acad. Sci. USA
95: 15072-15077
[Abstract][Full Text]
Power, C., Buist, R., Johnston, J. B., Del Bigio, M. R., Ni, W., Dawood, M. R., Peeling, J.
(1998). Neurovirulence in Feline Immunodeficiency Virus-Infected Neonatal Cats Is Viral Strain Specific and Dependent on Systemic Immune Suppression. J. Virol.
72: 9109-9115
[Abstract][Full Text]
(1998). Antiretroviral Therapy and Medical Management of Pediatric HIV Infection. Pediatrics
102: 1005-1062
[Full Text]
Coplan, J., Contello, K. A., Cunningham, C. K., Weiner, L. B., Dye, T. D., Roberge, L., Wojtowycz, M. A., Kirkwood, K.
(1998). Early Language Development in Children Exposed to or Infected With Human Immunodeficiency Virus. Pediatrics
102: 8e-8
[Abstract][Full Text]
Patterson, T. A., Binienda, Z. K., Lipe, G. W., Gillam, M. P., Slikker, W. Jr., Sandberg, J. A.
(1997). Transplacental Pharmacokinetics and Fetal Distribution of Azidothymidine, Its Glucuronide, and Phosphorylated Metabolites in Late-Term Rhesus Macaques after Maternal Infusion. Drug Metab. Dispos.
25: 453-459
[Abstract][Full Text]
BAUMEISTER, A. A., KUPSTAS, F. D., KLINDWORTH, L. M.
(1991). The New Morbidity: A National Plan of Action. American Behavioral Scientist
34: 468-500
Zabinski, R. A., Vance-Bryan, K., Rotschafer, J. C.
(1991). The Management of Central Nervous System Infections. Journal of Pharmacy Practice
4: 170-191
Mitsuya, H, Yarchoan, R, Broder, S
(1990). Molecular targets for AIDS therapy. Science
249: 1533-1544
[Abstract]
Yarchoan, R, Mitsuya, H, Thomas, R., Pluda, J., Hartman, N., Perno, C., Marczyk, K., Allain, J., Johns, D., Broder, S
(1989). In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine. Science
245: 412-415
[Abstract]
(1988). SHORT-TERM BENEFITS OF ZIDOVUDINE IN CHILDREN WITH AIDS. JWatch General
1988: 1-1
[Full Text]
